Core Viewpoint - New Morning Technology has announced the termination of its plan to acquire 96.9628% of Tianyi Enhua's shares due to a lack of agreement on key transaction terms after four months of negotiations [2][4][6]. Summary by Sections Termination of Acquisition - The company held a board meeting on August 11, 2025, where it approved the termination of the acquisition of Tianyi Enhua [3]. - The decision was made to protect the interests of the company and its investors after negotiations failed to reach consensus on core transaction terms [6]. Background of the Acquisition - In April 2023, New Morning Technology announced a major asset restructuring plan to acquire Tianyi Enhua through a combination of issuing shares and cash payments [8]. - Tianyi Enhua is recognized as a service provider in cloud computing infrastructure and has received accolades such as "Beijing Specialized and Innovative 'Little Giant' Enterprise" [8]. - The acquisition was expected to enhance New Morning Technology's capabilities in system integration services and expand its business scope in emerging technologies like blockchain and artificial intelligence [9]. Financial Performance - New Morning Technology reported a revenue of 1.349 billion yuan in 2024, a year-on-year decline of 22.22%, and a net profit loss of 81.4595 million yuan, marking its first loss since going public [11]. - The first quarter of 2025 showed a revenue of 124 million yuan, down 35.03% year-on-year, but the net loss improved to 6.2633 million yuan compared to the previous year [11].

Core Viewpoint - Shanghai Kaikai Industrial Co., Ltd. plans to transfer 11.11% equity stake in Nanjing Tianshi Software Technology Co., Ltd. to enhance asset utilization efficiency and focus on core business development [9][12][20] Group 1: Equity Transfer - The company intends to publicly transfer its 11.11% stake in Nanjing Tianshi through the Shanghai United Assets and Equity Exchange, with a minimum transfer price of 1,741.23 million RMB based on a pre-evaluation value of 15,672.62 million RMB as of December 31, 2024 [9][19][20] - The decision to transfer the stake was approved unanimously by the board of directors, with 9 votes in favor and no opposition [3][14] - The transaction does not constitute a related party transaction or a major asset restructuring, and it does not require shareholder approval [10][11][12] Group 2: Internal Loan Authorization - The company authorized an increase in the internal loan limit to its wholly-owned subsidiaries from 12 million RMB to 25 million RMB to support the transformation of its "big health" business strategy [4][5] - The internal loans will have an interest rate not lower than the prevailing loan market quotation rate (LPR) and can be reused [4][5] - This internal loan authorization aims to facilitate the rapid development of the subsidiaries' business without adversely affecting the company's financial health [4][5] Group 3: Company Strategy and Future Outlook - The equity transfer aligns with the company's strategic focus on enhancing investment efficiency and reducing investment risks, thereby optimizing its investment structure [13][20] - Post-transaction, the company will no longer hold any equity in Nanjing Tianshi, allowing it to concentrate resources on its core competencies and the "big health" industry transformation [13][20] - The company emphasizes that the transaction will not negatively impact its future financial status or operational results [21]